These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 37097774)

  • 1. EFFECTIVE HALF-LIFE, EXCRETION AND RADIATION EXPOSURE OF 177LU-PSMA.
    Parlak Y; Mutevelızade G; Sezgın C; Goksoy D; Gumuser G; Sayıt E
    Radiat Prot Dosimetry; 2023 Jun; 199(10):1090-1095. PubMed ID: 37097774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. External radiation exposure, excretion, and effective half-life in
    Kurth J; Krause BJ; Schwarzenböck SM; Stegger L; Schäfers M; Rahbar K
    EJNMMI Res; 2018 Apr; 8(1):32. PubMed ID: 29651569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Occupational Radiation Exposure of Radiopharmacy, Nuclear Medicine, and Surgical Personnel During Use of [
    Aalbersberg EA; Verwoerd D; Mylvaganan-Young C; de Barros HA; van Leeuwen PJ; Sonneborn-Bols M; Donswijk ML
    J Nucl Med Technol; 2021 Dec; 49(4):334-338. PubMed ID: 34330802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of radiation safety in (177)Lu-PSMA therapy and development of outpatient treatment protocol.
    Demir M; Abuqbeitah M; Uslu-Beşli L; Yıldırım Ö; Yeyin N; Çavdar İ; Vatankulu B; Gündüz H; Kabasakal L
    J Radiol Prot; 2016 Jun; 36(2):269-78. PubMed ID: 27089552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood clearance and occupational exposure for
    Abuqbeitah M; Demir M; Uslu-Beşli L; Yeyin N; Sönmezoğlu K
    Radiat Environ Biophys; 2018 Mar; 57(1):55-61. PubMed ID: 29149420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
    Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Clin Nucl Med; 2018 Jul; 43(7):486-491. PubMed ID: 29688951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Examining Absorbed Doses of Indigenously Developed
    Kamaldeep ; Wanage G; Sahu SK; Maletha P; Adnan A; Suman S; Basu S; Das T; Banerjee S
    Cancer Biother Radiopharm; 2021 Apr; 36(3):292-304. PubMed ID: 32379495
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate-Specific Membrane Antigen Radioligand Therapy Using
    Schuchardt C; Zhang J; Kulkarni HR; Chen X; Müller D; Baum RP
    J Nucl Med; 2022 Aug; 63(8):1199-1207. PubMed ID: 34887335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic, Dosimetry and Toxicity Study of ¹⁷⁷Lu-EDTMP in Patients: Phase 0/I study.
    Bal C; Arora G; Kumar P; Damle N; Das T; Chakraborty S; Banerjee S; Venkatesh M; Zaknun JJ; Pillai MR
    Curr Radiopharm; 2016; 9(1):71-84. PubMed ID: 25771371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Translation and First In-Human Use of [
    Eppard E; de la Fuente A; Benešová M; Khawar A; Bundschuh RA; Gärtner FC; Kreppel B; Kopka K; Essler M; Rösch F
    Theranostics; 2017; 7(18):4359-4369. PubMed ID: 29158832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation Dosimetry and Biodistribution of
    Piron S; De Man K; Van Laeken N; D'Asseler Y; Bacher K; Kersemans K; Ost P; Decaestecker K; Deseyne P; Fonteyne V; Lumen N; Achten E; Brans B; De Vos F
    J Nucl Med; 2019 Dec; 60(12):1736-1742. PubMed ID: 31028165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Damle NA; Shamim SA; Kumar R; Seth A; Bal C
    PLoS One; 2021; 16(5):e0251375. PubMed ID: 33970962
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation Protection and Occupational Exposure on
    Costa PF; Fendler WP; Herrmann K; Sandach P; Grafe H; Grootendorst MR; Püllen L; Kesch C; Krafft U; Radtke JP; Tschirdewahn S; Hadaschik BA; Darr C
    J Nucl Med; 2022 Sep; 63(9):1349-1356. PubMed ID: 34916249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiation Safety Precautions in (131)I Therapy of Graves' Disease Based on Actual Biokinetic Measurements.
    Liu B; Tian R; Peng W; He Y; Huang R; Kuang A
    J Clin Endocrinol Metab; 2015 Aug; 100(8):2934-41. PubMed ID: 26046966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiation Exposure to the Nuclear Medicine Personnel During Preparation and Handling of
    Thakral P; Sen I; Simecek J; Marx S; Kumari J; Kumar S; Tandon P; Dureja S; Pant V
    J Nucl Med Technol; 2020 Mar; 48(1):68-72. PubMed ID: 31604889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-therapeutic dosimetry of 177Lu-DKFZ-PSMA-617 in the treatment of patients with metastatic castration-resistant prostate cancer.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Nucl Med Commun; 2017 Jan; 38(1):91-98. PubMed ID: 27782913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
    Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
    J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer.
    Pfob CH; Ziegler S; Graner FP; Köhner M; Schachoff S; Blechert B; Wester HJ; Scheidhauer K; Schwaiger M; Maurer T; Eiber M
    Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1962-70. PubMed ID: 27207281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.
    Khawar A; Eppard E; Sinnes JP; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Clin Nucl Med; 2018 May; 43(5):323-330. PubMed ID: 29485430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.